• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1 Contact Hour(s)

    Release Date

    Sunday, October 15, 2017

    Offline Date

    Wednesday, April 4, 2018

    ACPE Expiration Date

    Monday, May 25, 2020

    Target Audience

    Pharmacist, Pharmacy Technician, Nurse

    Cost

    $0.00

    • Overview

      For many years it has been thought that enhancing the immune system against cancer could be a powerful tool in cancer therapy. While early approaches with IL-2 and interferon showed minimal activity it wasn't until more details of how T cells recognize cancer cells was discovered that more promising new therapies have been developed. It is now clear that there are "Immune Checkpoints" that help to control both antigen recognition of T cells as well as allow T cell destruction at the site of the tumor cells. While these checkpoints are designed to help prevent the T cells from recognizing self it is now clear that certain immune-checkpoint pathways are major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens. Because many of the immune checkpoints are ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval and now programmed cell death protein 1 (PD1 and PDL1) agents are also approved. This program will describe how these drugs work and the results seen in clinical trials. It will also describe side effects as well as interactions that a pharmacist should be aware of.

      Rating

         4.25  out of 5

      Handouts

      • Slide Document :   17086H01_4pp.pdf
      • Slide Document :   17086H01_2pp.pdf

      Financial Support By

      Merck & Co., Inc.
    • Pharmacist

      Define what “Checkpoints” are involved to turn T cells on and off
      Determine the types of immunological side effects potentially caused by checkpoint inhibitors
      Describe potential drug interactions including over the counter agents/complimentary therapies that pharmacist should understand in patients on checkpoint inhibitors
      Differentiate the indications for which checkpoint inhibitor agents are approved
      Describe the basic premise of how T cells work to kill cancer cells
      Describe the treatments and counseling points for the immunologic side effects seen with the checkpoint inhibitors

      Pharmacy Technician

      Identify what "Checkpoints" are involved to turn T cells on and off
      Describe the basic premise of how T cells work to kill cancer cells
      Recognize the available treatment options along with their appropriate indications for the checkpoint inhibitor agents included

      Nurse

      Describe the treatments and counseling points for the immunologic side effects seen with the checkpoint inhibitors
      Differentiate the indications for which checkpoint inhibitor agents are approved
      Describe the basic premise of how T cells work to kill cancer cells
      Determine the types of immunological side effects potentially caused by checkpoint inhibitors
      Describe potential drug interactions including over the counter agents/complimentary therapies that pharmacist should understand in patients on checkpoint inhibitors
      Define what “Checkpoints” are involved to turn T cells on and off
    • Activity Type

      Knowledge

      CE Broker

      20-600714

      Universal Activity Number

      Pharmacist 0798-0000-17-086-H01-P
      Pharmacy Technician 0798-0000-17-086-H01-T
      Nurse 0798-0000-17-086-H01-P

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

    • Faculty

      David  Frame, PharmD
      Assistant Professor, University of Michigan College of Pharmacy

    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).